ArticleChinese medical journal pulmonary and critical care medicine2025
Burden of non-COVID-19 lower respiratory infections and etiologies in China and globally: An analysis for the global burden of disease study 2021.
Article in Chinese medical journal pulmonary and critical care medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Frailty Increases the Risk and Frequency of Lower Respiratory Tract Infections in Older Adults: A Multicenter Prospective Cohort Study.Open forum infectious diseases · 2026Article
- Amplified inflammatory and immune responses in viral-associated pulmonary aspergillosis.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Non-COVID-19 lower respiratory infections (LRIs) represent a persistent public health concern in China and globally. However, comprehensive assessments of their long-term spatiotemporal trends remain limited. This study aimed to quantify the burden of LRIs by age, sex, and geographic region across China and globally from 1990 to 2021. Methods: Using standardized methodologies from the Global Burden of Disease Study 2021, we estimated LRI incidence and mortality globally and across 33 provincial-level units in China by sex, age, and year. Attributable incidence and mortality were further analyzed by underlying etiologies and risk factors, with corresponding 95 % uncertainty intervals. Results: In 2021, LRI accounted for 343.6 (95% UI: 325.2-363.5) million episodes and 2.2 (95% UI: 2.0-2.4) million deaths worldwide, corresponding to age-standardized incidence and mortality rates of 4283.6 (95% UI: 4057.0-4524.9) episodes per 100,000 population and 28.7 (95% UI: 25.9-31.1) per 100,000 population, respectively. This reflected a decline of 32.8 % and 53.6 % since 1990. China contributed 44.7 (95% UI: 41.8-47.8) million episodes and 206,930.2 (95% UI: 171,260.9-251,990.5) deaths in 2021, with respective age-standardized rates of 2853.8 (95% UI: 2664.0-3067.6) episodes per 100,000 population and 14.0 (95% UI: 11.7-17.0) per 100,000 population. Between 1990 and 2021, the age-standardized incidence and mortality rates in China declined by 47.9 % and 76.9 % which were higher than the global average. This progress was primarily driven by reductions in children under 5 years. Older individuals ≥70 years exhibited the highest burden. In 2021, Guangdong reported the highest age-standardized incidence, while Guizhou had the highest mortality. Conclusions: Despite marked improvements, LRIs remain a major contributor to morbidity and mortality in China, particularly among children and older adults. Addressing the residual burden will require targeted strategies, including enhanced diagnostics, expanded vaccination, air quality control, and strengthened healthcare in high-burden provinces.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.